This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 11-14, 2026
Hynes Convention CenterBoston, MA
Book Now
Menu
Book
keyboard_arrow_right

Main Conference - Day 2 (May 13)

keyboard_arrow_leftSearch & Filter
search
Main Conference - Day 2 (May 13)
search
Concurrent Tracks
Showing 1 of 1 Streams
8:25am - 8:30am
Co-Chairs' Remarks
  • Troels Koch, PhD - CTO & Scientific Advisor, NewCo
  • Rubina Parmar, - PhD, Atlas Ventures
8:30am - 9:00am
Conditionally Activated siRNA: Precision RNA Therapeutics through Cell-specific Activation
  • Charles Allerson, Ph.D - Chief Technology Officer, Switch Therapeutics
9:00am - 9:30am
Advancing ADAR RNA Editing Technology for Broad Applicability in Precision Medicines
  • Gerard Platenburg, PhD - Chief Scientific Officer, ProQR Therapeutics
9:30am - 10:00am
Targeting Fibroblasts in the Heart with Naked ASOs
  • Daniel Blessing - Chief Technology Officer & Scientific Co-Founder, HAYA Therapeutics
Showing 1 of 1 Streams
10:45am - 11:15am
Late Breaking Presentation
11:15am - 11:45am
Spatial Structured Oligonucleotides for RNA Therapeutics
  • Sudhir Agrawal - President and Founder, Arnay Sciences
11:45am - 12:15pm
Improving the Potency and Specificity of RNAi Therapeutics: Carbocyclic DNA and RNA Modifications
  • Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
12:15pm - 12:20pm
Transition to Spotlight Presentation Rooms
Concurrent Tracks
Showing 1 of 1 Streams
1:55pm - 2:00pm
Chairwoman's Remarks
  • Aimee Jackson, PhD - Founder, Jackson Bioscience Consulting
2:00pm - 2:30pm
Utilization of Oligonucleotides’ Half-Life to Optimize Dosing Regimen for Desirable Efficacy & Reduced CNS Toxicity
  • Meena PhD - SVP, Translational DMPK and Clinical Pharmacology, Stoke Therapeutics
2:30pm - 3:00pm
Investigational RNAi Therapeutics in Development for CNS Diseases
  • Vasant Jadhav, PhD - Chief Technology Officer, Alnylam Pharmaceuticals
3:00pm - 3:30pm
Cellular Correlates of Oligonucleotide-induced Neurotoxicity
  • Benjamin Andreone, PhD - Associate Director, Neuroscience, Atalanta Therapeutics
Showing 1 of 1 Streams
4:15pm - 4:45pm
FORCE Platform to Enable Delivery of Oligonucleotides for the Treatment of Neuromuscular Diseases
  • Saul Martinez Montero - Senior Director and Head of Oligonucleotide Therapeutics, Dyne Therapeutics
4:45pm - 5:15pm
Activating Anti-tumor Immunity with RNA/DNA Hybrid Agonists of TLR7/8/9
  • Art Krieg, MD - CEO, Zola Therapeutics
5:15pm - 5:45pm
Targeting the Lung, One Breath at a Time: The Great Promise of Splisense’s ASO Therapeutic Platform to Tackle a Wide Range of Pulmonary Diseases
  • Asaf Cohen - SVP, CMC and Operations, Splisense
Main Conference - Day 1 Keynote Sessions (May 12)
NextMain Conference - Day 3 (May 14)
Filter
Free / Premium
Streams
Clear
Choose Day